mTOR signalling has been identified as a core dysregulated pathway in ADPKD [68], and while mTOR inhibitors slow cyst growth in mice [105], clinical studies in humans have not yielded similar results and have demonstrated significant side effects, limiting the tolerated dose [102,103]. This evidence concerns the gene MTOR and autosomal dominant polycystic kidney disease.